Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia

Abstract
In a previous open-label study of hydroxyurea therapy, the synthesis of fetal hemoglobin increased in most patients with sickle cell anemia, with only mild myelotoxicity. By inhibiting sickling, increased levels of fetal hemoglobin might decrease the frequency of painful crises.